Motus GI Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MOTS research report →
Price Chart
About the company
Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures.
- CEO
- Mark Pomeranz
- IPO
- 2018
- Employees
- 15
- HQ
- Fort Lauderdale, FL, US
Get TickerSpark's AI analysis on MOTS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.28K
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.22
- Div Yield
- 0.00%
- Gross Margin
- -78.37%
- Op Margin
- -3732.60%
- Net Margin
- -4033.54%
- ROE
- -454.34%
- ROIC
- -230.98%
Latest fiscal year · YoY change
- Revenue
- $319.00K-46.1%
- Gross Profit
- $-250,000-22.5%
- Op Income
- $-11,907,000
- Net Income
- $-12,867,000+30.8%
- EPS
- $-15.89+81.6%
- OCF Growth
- +35.9%
- FCF Growth
- +36.1%
- 52W High
- $0.10
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -5.94
- RSI (14)
- 48
- Avg Volume
- 460
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Motus GI posted record quarterly revenue growth in Q3 as Pure-Vu EVS placements expanded, but management said capital budget delays and staffing shortages continue to slow some purchases.· November 14, 2022
- Q3 revenue was $278,000, up about 50% sequentially from Q2 and the highest quarterly revenue to date.
- Revenue was also up from $141,000 in the prior-year quarter; net loss was $5.0 million, or $1.69 per share.
- Pure-Vu EVS was in use at 25 hospitals at quarter-end, with management emphasizing repeat utilization and same-store growth.
- Management said some deals slipped into Q4 because of hospital capital budget constraints and staffing shortages.
- Cash was $13.3 million at September 30, 2022, and after a $5.5 million ATM equity sale, management said cash should fund operations into Q2 2023.
Third-quarter 2022 revenue was $278,000, compared with $141,000 in the same period last year, and represented an approximately 50% increase over Q2 2022. Net loss attributable to common shareholders was $5.0 million, or $1.69 per basic and diluted share, versus a net loss of $4.8 million, or $2.00 per share, last year. Net cash used in operating activities and for fixed assets was $3.8 million, versus $3.1 million a year ago. Cash and cash equivalents were $13.3 million at September 30, 2022, including the fully funded Kreos credit facility; after quarter-end, Motus sold about $5.5 million of shares under its ATM program, and management said cash is expected to meet anticipated needs through Q2 2023. No formal next-quarter or full-year revenue guidance was given.
Tim Moran said the quarter showed steady growth from the Pure-Vu EVS launch six months earlier, driven by product improvements and expanding commercial reach. He framed the strategy as a mix of deeper penetration within current accounts and targeted expansion into new hospitals, with repeat utilization seen as key to creating predictable recurring revenue. He was optimistic about the pipeline, especially the VA system and future catalysts like outpatient reimbursement data and the upper GI device, while acknowledging that some buying decisions are still delayed by capital and staffing issues.
Andrew Taylor highlighted the hard numbers: $278,000 in Q3 revenue, $5.0 million net loss attributable to common shareholders, and $3.8 million of cash used in operations and fixed assets. He said revenue was primarily from disposable sleeve reorders/new orders plus limited workstation sales and rentals. He also noted $13.3 million of cash and cash equivalents at quarter-end, the fully funded Kreos facility with no financial or liquidity covenants, and that the post-quarter $5.5 million ATM sale extends expected liquidity into Q2 2023.
Analysts pressed management on whether deals delayed into Q4 are likely to close, what a high-volume site looks like, and how the sales team balances new placements versus driving usage in existing accounts. Tim said the delayed purchases were mostly capital deals that had been expected in Q3 and are now targeted for Q4, and that accounts doing north of 10 procedures per month are the ones where utilization tends to become more self-sustaining. On the VA opportunity, management said there are 15 to 20 near-term targets and that, over the next few quarters, closing several per quarter is realistic. They also said colonoscopy volumes appear back to normal post-COVID, but capital constraints and staffing shortages are still lengthening sales cycles.
The bull case from this call is that Pure-Vu EVS appears to be gaining real traction: revenue hit a quarterly record, placements reached 25 hospitals, and management described repeat utilization as improving in some accounts by 20% to 40% quarter over quarter. The VA designation, early system-wide approvals, and a planned outpatient reimbursement study all give the company multiple ways to expand beyond the initial launch footprint.
The bear case is that the business is still very small and dependent on a limited sales organization, so growth can be uneven and vulnerable to delays in hospital capital spending. Management repeatedly pointed to staffing shortages and budget constraints as reasons some orders slipped to Q4, and reimbursement is still a hurdle in the outpatient market until further data are generated.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 90.3%
- Shares Outstanding
- 6.39M
- Float Shares
- 5.77M
of shares held by institutions
20 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Advisor Group, Inc. | 1.00K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 5, 24 | Durbin Scott | other | 23,205 |
| Mar 5, 24 | Nelson Sonja | other | 23,205 |
| Mar 5, 24 | Pruden Gary J | other | 23,205 |
| Mar 5, 24 | Moran Timothy P. | other | 23,205 |
| Sep 12, 23 | Orchestra BioMed Holdings, Inc. | other | 0 |
| Sep 12, 23 | Orchestra BioMed Holdings, Inc. | other | 0 |
| Sep 6, 23 | Durbin Scott | other | 2,500 |
| Sep 6, 23 | Durbin Scott | other | 0 |
| Jun 2, 23 | Ram Ravit | other | 0 |
| Jun 2, 23 | Ram Ravit | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MOTS coverage
Recent articles, reports, and earnings notes.
No research on MOTS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MOTS report →Vanta Commends U.S. FDA Advisory Committee Vote Recommending Inclusion of Six Peptide Substances on FDA's 503A Bulks List, Including BPC-157, TB-500 and MOTS-c
accessnewswire.com · Jul 28
Why Is Motus GI (MOTS) Stock Down 37% Today?
investorplace.com · Apr 12
Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
globenewswire.com · Mar 18
EndoSound™ Inc., Appoints Medical Device Commercial Leader Scott Aldrich Jr as Chief Executive Officer
businesswire.com · Feb 29
Motus GI Holdings, Inc. Announces Exercise of Warrants for $2.7 Million Gross Proceeds
globenewswire.com · Feb 22
Motus GI Holdings Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu® System to Avoid Clogging in Cleansing the GI Tract
globenewswire.com · Feb 21
Motus GI Holdings, Inc. Announces Adjournment of the February 16, 2024 Special Meeting of Stockholders
globenewswire.com · Feb 16
Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E
zacks.com · Feb 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.